Menu Member Login
For Patients/Caregivers
Patient Financial Resources
FDA Approvals
Idaho Society of Cancer Oncology
The Idaho Society of Clinical Oncology (ISCO) represents Idaho physicians and related health care professionals who care for cancer patients. The Society is a non-profit corporation devoted to the improvement of hematologic and oncologic care of patients.
Membership in the Society is open to all professionals whose primary endeavor is the delivery of oncology care, including physicians, nurse practitioners, physician assistants and pharmacists. Membership is restricted to those individuals primarily delivering care in the State of Idaho and is FREE to qualified professionals
Economic Cost of Cancer in U.S. Tops $94B Annually According to a Study
State-by-state variations in cancer deaths suggest that effective cancer prevention and treatment could yield economic benefits, according to a study published in JAMA Oncology.
Click here for more.
Denial Rates and Days to Pay for Cancer Drugs: Commercial Health Plan Report Card
Office-administered oncology drugs given in the community setting face stiff reimbursement challenges when billing commercial plans; while Medicare has emerged as the gold standard for both predictable payment and timeliness.
CDC Issues Key Clarification on Guideline for Prescribing Opioids for Chronic Pain
Agency Clarifies CDC Guideline Not Meant to Limit Access to Appropriate Pain Management for Individuals with Cancer, Sickle Cell Disease
ISCO Fall Meeting
The Grove Hotel | Boise
ASH Meeting on Hematologic Malignancies
Fairmont Chicago, Millennium Park, Chicago, IL
Janssen provides discussion paper for 2020 Medicare Hospital Inpatient Prospective Payment System (IPPS) Proposed Rule.
The CMS fact sheet is available here. In the FY 2020 IPPS Proposed Rule, CMS addresses how the agency proposes to pay for CAR T-cell therapy administered on an inpatient basis.
COA Launches Major National Campaign to Stop PBM Abuses and Highlight Patient Horror Stories
COA recently launched a major national campaign to highlight the negative impact of pharmacy benefit managers (PBMs) on patients with cancer. The "PBM Abuses" campaign will ensure that PBM middlemen's abuse of patients with cancer is not lost in policy deliberations in Washington.
CMS' "Fail First" Step Therapy Policy Means Medicare Patients with Cancer Will Face More Dangerous Delays and Denials
Earlier this month, the Centers for Medicare & Medicaid Services (CMS) codified its decision to allow MA plans to use "fail first" step therapy for new starts of Part B drugs for cancer and other serious diseases. The Trump administration's decision to finalize step therapy in MA plans means that Medicare patients with cancer will face nightmares of delays and denials while trying to access their physician-prescribed treatments
ASTRO releases updated radiation oncology safety guide
In conjunction with Patient Safety Awareness Week, the American Society for Radiation Oncology (ASTRO) published an update today to its framework for safe and effective radiation therapy treatment. The comprehensive reference guide, Safety is No Accident: A Framework for Quality Radiation Oncology and Care, is available for download.
Learn more about the big changes to the ASH Scholar Award program.
More people are now eligible for the ASH Scholar Awards than ever before. The new Fellow to Faculty Scholar Award offers financial support to those preparing to compete for independent faculty-level positions in the next two to three years.
© Copyright 2019 Idaho Society of Clinical Oncology
550M Ritchie Highway, #271, Severna Park, MD 21146 | phone: 208-901-3353 | Email: [email protected]
Credit Card Processing Phone Line: 1-855-605-PAID (7243)